← Back to all signals
RESEARCH PAPER ANALYSIS

Microstructural alterations of parafascicular nucleus pathways associated with freezing of gait in Parkinson's disease.

AI interpretation is pending for this paper.

PMID42183045
JournalBrain communications
Publication Date2026-01-01
Ingested2026-05-25 12:45 PM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

The parafascicular nucleus (Pf) projects to the dorsal putamen (Dpu), subthalamic nucleus (STN) and nucleus accumbens (Nac), regions implicated in both motor and non-motor symptoms of Parkinson's disease. However, microstructural alterations of these pathways across different Parkinson's disease motor subtypes remain unclear and heterogeneity within the postural instability and gait disorder (PIGD) subtype, particularly with respect to the presence or absence of freezing of gait (FOG), has often been overlooked. Therefore, this study employed diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI) to examine microstructural properties of Pf projections in patients with tremor-dominant Parkinson's disease (PDTD; n = 25), PIGD (n = 34) and healthy controls (HC; n = 38). PIGD patients were further divided into patients with FOG (PIGD-FOG; n = 21) and patients without FOG (PIGD-nFOG; n = 13), and microstructural metrics were comprehensively assessed and compared between the two subgroups. The discrimination effects of microstructural metrics in Pf pathways were detected using receiver operating characteristic (ROC) analyses, and the correlations between microstructural metrics and clinical features of Parkinson's disease were further analysed. Group comparisons revealed significant differences between the PIGD and HC groups, whereas no significant differences were observed between the PDTD and HC groups or between the PDTD and PIGD groups. Compared with HC, PIGD patients exhibited significant microstructural impairments in Pf-related pathways, with reduced fractional anisotropy (FA) and neurite density (NDI), along with increased axial diffusivity (AD), mean diffusivity (MD) and radial diffusivity (RD) (P < 0.05). Within the PIGD group, patients with FOG showed more severe degeneration of Pf pathways, particularly in the bilateral Pf-STN pathways. Specifically, FA and NDI values were reduced, while MD and RD values were increased in PIGD-FOG patients compared with PIGD-nFOG patients (P < 0.05). ROC analyses demonstrated that microstructural metrics in Pf pathways effectively discriminated PIGD-FOG from PIGD-nFOG patients. Moreover, microstructural impairments of Pf pathways were associated with more severe gait dysfunction, more advanced disease stage and poorer motor-related activities of daily living in PIGD patients and with greater FOG severity, cognitive impairment and worse motor-related activities of daily living in the PIGD-FOG subgroup. These findings indicate that microstructural alterations of Pf pathways are preferentially associated with the PIGD subtype and are more pronounced in patients with FOG. Together, these results underscore a strong association between Pf-related circuits and FOG in PIGD and highlight the importance of symptom-driven heterogeneity within motor subtypes.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic